주식/증권
📉 부정적
CMPX Plunge Wipes Out $104M After FDA Demands Fresh Trial For Cancer Drug — Wedbush Sees Another 19% Downside
요약
Compass said on Tuesday that the FDA recommended a trial showing a survival benefit before the company files a biologics license application for tovecimig in previously treated advanced biliary tract cancer.